Analysis of the tumor length and other prognosis factors in pT1-2 node-negative esophageal squamous cell carcinoma in a Chinese population

Song, Zhengbo; Wang, Jiwen; Lin, Bing; Zhang, Yiping

doi:10.1186/1477-7819-10-273

Cited by 22 publications

(27 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results are consistent with previous studies (Wang et al, 2011;Song et al, 2012;Feng et al, 2013). In our study, the esophageal tumor length had a significant impact on survival of patients in N0 and N1 (p=0.01- Figure.4) that is contrary to the result reported by Feng et al (2013) who suggested that tumor length is not a prognostic factor for ESCC patients with N staging (p=0.119).…”

Section: Discussionsupporting

confidence: 90%

“…Similar results were reported by Davies et al (2012) indicating that tumor length was a prognostic factor for survival in univariate analysis. There are several reports who demonstrated tumor length as a prognostic factor for survival in univariate analysis; as well as a multivariate analysis (Gaur et al, 2011;Wang et al, 2011;Song et al, 2012;Feng et al, 2013). In the current study, tumor length was a prognostic factor after controlling the factor of tumor stage (p=0.02) but a multivariate statistical analysis was not possible for the tumor length.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Impact of Tumor Length on Survival for Patients with Resected Esophageal Cancer

Mirinezhad

Jangjoo²,

Seyednejad³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: Tumor length in patients with esophageal cancer (EC) has recently received great attention. However, its prognostic role for EC is controversial. The purpose of our study was to characterize the prognostic value of tumor length in EC patients and offer the optimum cut-off point of tumor length by reliable statistical methods. Materials and Methods: A retrospective analysis was conducted on 71 consecutive patients with EC who underwent surgery. ROC curve analysis was used to determine the optimal cut-off point for tumor length, measured with a handheld ruler after formalin fixation. Correlations between tumor length and other factors were surveyed, and overall survival (OS) rates were compared between the two groups. Potential prognostic factors were evaluated by univariate Kaplan-Meier survival analysis. A P value less than 0.05 was considered significant. Results: There were a total of 71 patients, with a male/ female divide of 43/28 and a median age of 59. Characteristics were as follows: squamous/adenocarcinoma, 65/6; median tumor length, 4 (0.9-10); cut-off point for tumor length, 4cm. Univariate analysis prognostic factors were tumor length and modality of therapy. One, three and five year OS rates were 84, 43 and 43% for tumors with ≤4cm length, whereas the rates were 75, 9 and 0% for tumors >4 cm. There was a significant association between tumor length and age, sex, weight loss, tumor site, histology, T and N scores, differentiation, stage, modality of therapy and longitudinal margin involvement. Conclusions: Future studies for modification of the EC staging system might consider tumor length too as it is an important prognostic factor. Further assessment with larger prospective datasets and practical methods (such as endoscopy) is needed to establish an optimal cut-off point for tumor length.

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Discussionmentioning

confidence: 99%

Impact of Tumor Length on Survival for Patients with Resected Esophageal Cancer

Mirinezhad

Jangjoo²,

Seyednejad³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…This is in agreement with reported studies (Sucimachi et al, 1986;Urba et al, 2001;Song et al, 2012).…”

Section: Discussionsupporting

confidence: 94%

“…There was significant OS advantage in upper and middle thirds compared to lower third in CRT group (p=0.009) and a trend to survival advantage in surgery group (p=0.066). This is confirmed by reported studies (Sucimachi et al, 1986;Teoh et al, 2012;Song et al, 2012).…”

Section: Discussionsupporting

confidence: 89%

Chemoradiation Compared to Surgery Alone in Patients With Non- Metastatic Esophageal Carcinoma

Elsayed¹,

Maximos²

2014

CCO

View full text Add to dashboard Cite

Purpose: To assess overall survival (OS) of esophageal cancer patients treated either by esophagectomy or chemoradiation (CRT). Methods:The medical records of patients with non metastatic esophageal cancer, treated with esophagectomy and those treated with concurrent CRT were analyzed. For all patients, files were reviewed for age, sex, tumor site and type, grade, disease stage and survival. The Log-rank test was used to examine differences in OS rates. Results:The medical records of 90 patients were analyzed. After a median follow up of 20 months, 2-year OS rate for the whole group was 46%. There was significant differences in 2-year OS in favor of patients treated by concurrent CRT (55.4%) compared to those treated by surgery (31%) (p=0.016, HR:1.96, 95% CI: 1.13-3.38). Univariate analysis showed that patients in each treatment group, had comparable 2-year OS rates regarding patient's age, gender, pathologic subtype, and histologic grade (p>0.05). Disease stage in each group and tumor site in CRT group significantly affected OS rates (p<0.05). Conclusions:Survival rates were statistically significant higher in patients treated with CRT than in those underwent esophagectomy. Prognostic factors that affected survival were disease stage in each treatment group and tumor site in CRT group.

show abstract

“…In Table 5 and Figure 1, we demonstrate that fewer TDLN, tumor length exceeding 3.5 cm, resection margin invasion, and N-positive status are four independent variables that indicate poor outcomes with elevated HR for ESCC patients. The prognostic roles of tumor length and resection margin invasion in ESCC have recently been discussed by several researchers [9][10][11][12][13]. The current AJCC T status mainly focuses on the depth of tumor invasion (vertical) without mention of the tumor length (horizontal).…”

Section: Commentmentioning

confidence: 99%